Uptown aces free spins 2016. 5104-201A: Osteoporosis Update 2015
It’s All About the Fractures

• Monstrata Fracture Mac Os 11
• Monstrata Fracture Mac Os Catalina

Monstrata Fracture: Developer: Astralore Games: Publishers: Astralore Games: Description. I knew college would be a different experience, but I didn't expect it to be a different world! I should have known something was up when the main campus burned down and I. Boot Camp is a utility that comes with your Mac and lets you switch between macOS and Windows. Download your copy of Windows 10, then let Boot Camp Assistant walk you through the installation steps for Intel-based Macs. Get started with Boot Camp. Monstrata Fracture A downloadable game for Windows, macOS, and Linux Download NowName your own price I knew college would be a different experience, but I didn't. Fracture XT features a new Granular Processor, a totally revamped Buffer Effects Processor, a revamped Delay Effects Processor and dedicated multi-mode filters. In addition, you have access to 4 LFOs with various waveshapes, slow rates, sync to host and the ability to.

Monstrata Fracture Mac Os 11

Recording of a live webinar presented on May 14, 2015

A certified one-hour prerecorded webinar for radiologists, radiologic technologists, endocrinologists, rheumatologists, primary care physicians, orthopaedists, and other healthcare providers who assess patients for osteoporosis and fracture risk.

Click ENROLL NOW to register for this program

Course Overview
Osteoporosis remains a major public health concern in the United States. While in large part it can be prevented and treated, osteoporosis continues to be underdiagnosed and undertreated. As a result, many patients are not receiving the benefits of therapy or life style changes in the early phase of the disease when intervention is most effective. 1, 2

This educational activity will include information on the clinical criteria for performing bone mineral density testing (BMD), why osteoporosis is underdiagnosed and undertreated, assessments in addition to BMD that together more accurately reflect the patient’s bone health status, and tips for helping prevent primary and secondary fracture.

1. National Osteoporosis Foundation. Clinician’s Guide to Prevention and Treatment of Osteoporosis. Washington, DC: National Osteoporosis Foundation; 2010.

2. Siris ES, Adler R, Bilezikian, et al. Osteoporos Int. The clinical diagnosis of osteoporosis: a position statement from the National Bone Health Alliance Working Group. 2014;25(5):1439-1443.

Educational Objectives
At the conclusion of this activity, participants should be better able to:

• Discuss the impact of undiagnosed osteoporosis on the US health care system and on patients who are at risk for osteoporosis-related fracture
• Describe how other methods of assessing bone health, in addition to BMD, will more accurately identify patients at risk for osteoporosis and fracture
• Implement strategies to help prevent secondary fracture in osteoporotic patients who have already sustained a break

ACCME Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and International Center for Postgraduate Medical Education. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation
Physicians
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

SA-CME: This activity meets the criteria for self-assessment toward the purpose of fulfilling requirements in the American Board of Radiology (ABR) Maintenance of Certification Program.

The European Accreditation Council for CME (EACCME®)
The UEMS-EACCME® has mutual recognition agreements with the American Medical Association (AMA) for live events and e-learning materials. For more information go to https://www.ama-assn.org/education/uemseaccme-cme-credit-recognition.

Radiologic Technologists
This program has been approved by the American Society of Radiologic Technologists (ASRT) for 1.0 hour of ARRT Category A continuing education credit.

How to Enroll and Participate
There are no fees or prerequisites to participate in this program. Estimated time to complete this activity is one hour.

• Click ENROLL NOW, CONTINUE, CONFIRM ORDER, and ACCESS COURSE NOW.
• Click on the blue link. Complete the precourse questions and SUBMIT.
• Click on the blue link again to view the recording.

How to Receive a Credit Certificate
Your certificate of credit will remain in your account at www.icpme.us as a permanent record of your participation.

• Log-in to your account at www.icpme.us
• View the entire educational activity session. At the conclusion of the lecture, close the Vimeo window.
• Return to the course in your account at www.icpme.us.
• From the COURSE HOME page, click the button for POSTTEST and for EVALUATION.
• A passing grade of at least 75% is required to receive credit. You may take the test up to three times.
• Upon receipt of a passing grade, you will be able to print a certificate of credit from your account at www.icpme.us

Your certificate of credit will remain in your account at www.icpme.us as a permanent record of your participation.
Faculty

Ethel S. Siris, MD
Dr. Siris is the Madeline C. Stabile Professor of Medicine at Columbia University Medical Center, and Director of the Toni Stabile Osteoporosis Center, Columbia University Medical Center, New York-Presbyterian Hospital, in New York, New York. A graduate of Radcliffe College, Harvard University, she received her MD from the Columbia University College of Physicians and Surgeons. She is an endocrinologist who works as a clinician, clinical investigator and medical educator, all in the area of metabolic bone diseases, particularly osteoporosis and Paget’s disease of bone. She has participated in research with osteoporosis medications, including bisphosphonates, selective estrogen receptor modulators (SERMS), and RANK ligand inhibitors, and served as the leader of the National Osteoporosis Risk Assessment Program (NORA). Most recently her research has focused on risk factors for fracture and treatment adherence with osteoporosis medications.

Dr. Siris is also actively engaged in several public policy initiatives to create quality improvement in secondary fracture prevention and in osteoporosis diagnosis in the US. She is the clinical chair of a Joint Commission Technical Advisory Panel that has put forward quality measures for post fracture osteoporosis evaluation and treatment. She was the co-chair of the ASBMR Task Force on secondary fracture prevention that called for the establishment of Fracture Liaison Services in the US, to increase the number of older patients with fragility fractures who are assessed and treated medically as appropriate to prevent future fractures for which they are at high risk. Recently Dr. Siris led a National Bone Health Alliance Working Group that proposed and published a consensus paper expanding the criteria for the clinical diagnosis of osteoporosis, to assure that postmenopausal women and older men with an increased risk of fractures are identified.

Dr. Siris is a Trustee of the National Osteoporosis Foundation and is also a past president of NOF. She previously served on the Board of Trustees of the International Osteoporosis Foundation and is currently a member of the Executive Committee of the National Bone Health Alliance in the US.

Disclosure Information
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. The existence or absence of COI for anyone in a position to control content will be disclosed to participants prior to the start of each activity.

The faculty has reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Ethel S. Siris, MD has received consulting fees from Amgen, Eli Lilly, Merck, Novartis, AgNovos, and Radius.

Datalogic magellan 1100i driver download. The following planners and managers have reported NO financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Sharon Cancino
Trace Hutchison, PharmD
Samantha Mattiucci, PharmD, CCMEP
Linda McLean, MS
Victoria Phoenix, BS
Jan Schultz, RN, MSN, CCMEP
Judi Smelker-Mitchek, RN, BSN

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Questions
For questions regarding this program, please contact ICPME:
Email: information@icpmed.com
Jointly provided by

Monstrata Fracture Mac Os Catalina

This activity is supported by an independent educational grant from Hologic, Inc.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.